Format

Send to

Choose Destination
See comment in PubMed Commons below
Psychiatr Clin North Am. 2012 Sep;35(3):661-81. doi: 10.1016/j.psc.2012.06.007. Epub 2012 Jul 24.

Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Author information

1
The Zucker Hillside Hospital, Division of Psychiatry Research, North Shore-LIJ Health System, 75-59, 263rd Street, Glen Oaks, NY 11004, USA. ccorrell@lij.edu

Abstract

Antipsychotic polypharmacy (APP) is common in the treatment of schizophrenia spectrum disorders. The literature indicates that APP is related to patient, illness, and treatment variables that are proxy measures for greater illness acuity, severity, complexity, and chronicity. The largely unknown relative risks and benefits of APP need to be weighed against the known risks and benefits of clozapine for treatment-resistant patients. To inform evidence-based clinical practice, controlled, high-quality antipsychotic combination and discontinuation trials are necessary to determine the effectiveness, safety, and role of APP in the management of severely ill patients with insufficient response to antipsychotic monotherapy.

PMID:
22929872
PMCID:
PMC3717367
DOI:
10.1016/j.psc.2012.06.007
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center